Kestra Advisory Services
ARQT icon

Kestra Advisory Services’s Arcutis Biotherapeutics ARQT Stock Holding History

Kestra Advisory Services’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-7,850
Closed -$206K – 3450
2026
Q2 		$206K Sell
7,850
-1,036
-12% -$24.1K ﹤0.01% 3087
2026
Q1 		$209K Sell
8,886
-560
-6% -$14.3K ﹤0.01% 2918
2025
Q4 		$274K Sell
9,446
-674
-7% -$17.3K ﹤0.01% 2616
2025
Q3 		$191K Sell
10,120
-1,430
-12% -$22.6K ﹤0.01% 2752
2025
Q2 		$162K Buy
+11,550
New +$162K ﹤0.01% 2686

Other funds holding ARQT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Perpetual Ltd
Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Jay A. Fishman Ltd
Jay A. Fishman Ltd Troy, Michigan $1.24B AUM 21.21% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return

Kestra Advisory Services's ARQT Position: Q3 2026 in Review

Kestra Advisory Services sold out of Arcutis Biotherapeutics (ARQT) in Q3 2026, closing a stake of 7,850 shares — an estimated $206K sold.

Kestra Advisory Services first reported a position in ARQT in Q2 2025 and held it in 5 quarters. The position peaked at $274K in Q4 2025. 112 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • Kestra Advisory Services reported no remaining Arcutis Biotherapeutics position as of Q3 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 7,850 Arcutis Biotherapeutics shares in Q3 2026, an estimated $206K.
  • Kestra Advisory Services first reported a position in Arcutis Biotherapeutics in Q2 2025 and held it in 5 quarters.
  • Kestra Advisory Services's Arcutis Biotherapeutics position peaked at $274K in Q4 2025.
  • 112 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on Kestra Advisory Services's 13F filing for Q3 2026, filed 2 Nov 2026.